R&D News | pharmaphorum

News

Ambros' $125m for pain disorder drug, and other financings

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

News

Lilly points to long-lasting weight loss with orforglipron

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

Takeda plans filings for Sotyktu rival on new psoriasis data

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

DBV gets peanut allergy therapy programme back on track

Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.

News

Editor's Picks